drugset
drugset / Trial / NCT05521269

Dose Study of ANX1502 in Healthy Volunteers

NCT05521269 ↗

Phase 1 Completed 135 enrolled Annexon, Inc.
RandomizedSequentialDouble-blindBasic science

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ANX1502 (prodrug) and ANX1439 (active drug) in healthy participants.

Timeline

Start
2022-06-27
Primary completion
2024-11-19
Completion
2024-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX1502 Unknown — Oral

Indications

No indication recorded.